New chemotheraphy drug approved by the FDA
The U.S. Food and Drug Administration (FDA) has recently approved a new drug for the treatment of the advanced stage of prostate cancer. The chemotherapy drug Jevanta was reviewed under the FDA’s priority review program which provides for and expedited review for drugs that may offer advances in treatment.
“With the approval of Jevtana, health-care professionals now have a new treatment option for patients with the most advanced stage of prostate cancer and for whom there have been few options.” Oliver Sartor, principal investigator of the Phase 3 clinical study
